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tier drug beneﬁt plan at a managed care plan in Toledo-
Ohio, were reviewed retrospectively. The top ten therapy
classes based on net costs to the health plan were selected
for analysis. The records for these classes were extracted
using the Rx Clients Report v 5.0 software at the health
plan. Data were analyzed using Microsoft Excel 2000.
RESULTS: On average 1) PMPM ingredient costs
increased 16.5% for the preferred drugs and decreased
7.4% for the non-preferred drugs; 2) PMPM utilization
increased 19.3% for the preferred drugs and decreased
12.7% for the non–preferred drugs and; 3) Ingredient
cost per prescription increased 2.8% for the preferred
drugs and also increased 4.7% for the non-preferred
drugs. The increase in the PMPM ingredient costs and
PMPM utilization maybe due to the utilization of the
most expensive preferred drugs on the formulary. The
ingredient costs per prescription were not skewed either
towards the preferred or the non-preferred drugs.
CONCLUSION: The implementation of a three-tier drug
co-payment caused a decrease in the PMPM ingredient
costs and PMPM utilization of the non-preferred drugs.
It generated cost-savings to the managed care plan over
a period of two years by shifting the members from 
high cost non-preferred drugs to the lower cost preferred
drugs.
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Economic evaluation of medical technologies in Japan is
challenging because of a lack of data sources.
OBJECTIVE: This paper reviews the data sources avail-
able for conducting pharmacoeconomics research in
Japan, and discusses health policy reforms that may
increase the demand for pharmacoeconomics studies in
the future.
METHODS: A literature review of pharmacoeconomic
studies was conducted in both English (MEDLINE 
OHE-HEED) and Japanese publications (JAPICDOC) to
identify the typical data sources used in these studies.
Reﬂecting on ﬁrst hand experience conducting outcomes
research in Japan, we summarized (percent of studies 
utilizing the different data source types) and commented
on the data sources.
RESULTS: A total of 42 published studies were found 
in the Japanese and English literature from 1980–2001.
Typical sources identiﬁed for resource utilization data
included: clinical trials (62%), epidemiology/case studies
(43%), patient chart reviews (52%), expert panels (12%).
Sources for clinical efﬁcacy or disease state transition
probabilities included: clinical trials (60%), epidemiol-
ogy/case studies (36%), patient chart reviews (29%),
expert panels (12%). The cost data sources identiﬁed
were: 1) national uniform reimbursement fees (98%)—
Japanese Ministry of Health, Labor and Welfare
(MHLW), 2) micro-cost studies (2%). The MHLW
uniform fees represent costs from the health insurance
plan viewpoint, and therefore are relevant in drug price
negotiations with the MHLW. Demand for pharma-
coeconomic data may increase because of: 1) upcoming
MHLW pharmaceutical pricing and/or health insurance
system reforms; 2) new regulatory committees e.g. NICE.
CONCLUSION: Access to data sources for pharma-
coeconomic research is generally known to be limited 
in Japan, however several published studies effectively
overcame such limitations. Compared to other countries,
however, detailed population-based data are still rela-
tively unavailable. Upcoming health care reforms may
increase the demand for pharmacoeconomic data in
Japan, thus, increasing the demand for better sources of
data typically needed for these studies.
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OBJECTIVE: Although there are nearly a quarter of a
million hospitalizations for traumatic brain injury (TBI)
in the U.S. each year, economic data on TBI treatment are
limited. The purpose of this study was to estimate the out-
comes and costs of acute inpatient treatment of TBI.
METHODS: Using a large, geographically-diverse, multi-
hospital database, we examined inpatient records for
persons aged 16 years or older who were hospitalized for
TBI between January 1, 1997 and June 30, 1999. Patients
were stratiﬁed by TBI severity using an adaptation of 
the Abbreviated Injury Scale for administrative data
(ICD/AIS), as follows: 2, “moderate”; 3, “serious”; 4,
“severe”; and 5, “critical”. Patient characteristics, pat-
terns of treatment, and outcomes and costs were exam-
ined by injury severity and mechanism of injury. Costs of
treatment were estimated from billed charges using cost-
to-charge ratios from the Medicare Prospective Payment
System.
RESULTS: Of 8,717 study subjects identiﬁed, 12.5% had
moderate, 44.8% serious, 29.6% severe, and 13.2% 
critical TBI. Falls were the most common reported cause
of injury (40.8%), followed by motor-vehicle accidents
(39.3%), blows to the head (11.3%), and gunshot
wounds (2.4%). Average length of stay in hospital ranged
from 6.7 days for moderate TBI to 17.5 days for critical
TBI. The overall rate of death in hospital was relatively
low among patients with moderate (1.3%), serious
(5.7%), and severe (8.7%) TBIs, but much higher among
the most critically injured patients (52.0%). Costs of hos-
